Article

Adult bone marrow-derived cells for cardiac repair - A systematic review and meta-analysis

Harvard University, Cambridge, Massachusetts, United States
Archives of Internal Medicine (Impact Factor: 13.25). 05/2007; 167(10):989-97. DOI: 10.1001/archinte.167.10.989
Source: PubMed

ABSTRACT The results from small clinical studies suggest that therapy with adult bone marrow (BM)-derived cells (BMCs) reduces infarct size and improves left ventricular function and perfusion. However, the effects of BMC transplantation in patients with ischemic heart disease remains unclear.
We searched MEDLINE, EMBASE, Science Citation Index, CINAHL (Cumulative Index to Nursing and Allied Health), and the Cochrane Central Register of Controlled Trials (CENTRAL) (through July 2006) for randomized controlled trials and cohort studies of BMC transplantation to treat ischemic heart disease. We conducted a random-effects meta-analysis across eligible studies measuring the same outcomes.
Eighteen studies (N = 999 patients) were eligible. The adult BMCs included BM mononuclear cells, BM mesenchymal stem cells, and BM-derived circulating progenitor cells. Compared with controls, BMC transplantation improved left ventricular ejection fraction (pooled difference, 3.66%; 95% confidence interval [CI], 1.93% to 5.40%; P<.001); reduced infarct scar size (-5.49%; 95% CI, -9.10% to -1.88%; P = .003); and reduced left ventricular end-systolic volume (-4.80 mL; 95% CI, -8.20 to -1.41 mL; P = .006).
The available evidence suggests that BMC transplantation is associated with modest improvements in physiologic and anatomic parameters in patients with both acute myocardial infarction and chronic ischemic heart disease, above and beyond conventional therapy. Therapy with BMCs seems safe. These results support conducting large randomized trials to evaluate the impact of BMC therapy vs the standard of care on patient-important outcomes.

0 Bookmarks
 · 
156 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Regenerating the human heart is a challenge that has engaged researchers and clinicians around the globe for nearly a century. From the repair of the first septal defect in 1953, followed by the first successful heart transplant in 1967, and later to the first infusion of bone marrow-derived cells to the human myocardium in 2002, significant progress has been made in heart repair. However, chronic heart failure remains a leading pathological burden worldwide. Why has regenerating the human heart been such a challenge, and how close are we to achieving clinically relevant regeneration? Exciting progress has been made to establish cell transplantation techniques in recent years, and new preclinical studies in large animal models have shed light on the promises and challenges that lie ahead. In this review, we will discuss the history of cell therapy approaches and provide an overview of clinical trials using cell transplantation for heart regeneration. Focusing on the delivery of human stem cell-derived cardiomyocytes, current experimental strategies in the field will be discussed as well as their clinical translation potential. Although the human heart has not been regenerated yet, decades of experimental progress have guided us onto a promising path. Previous work in clinical cell therapy for heart repair using bone marrow mononuclear cells, mesenchymal stem cells, and cardiac-derived cells have overall demonstrated safety and modest efficacy. Recent advancements using human stem cell-derived cardiomyocytes have established them as a next generation cell type for moving forward, however certain challenges must be overcome for this technique to be successful in the clinics. Copyright © 2015. Published by Elsevier Inc.
    Cardiovascular pathology: the official journal of the Society for Cardiovascular Pathology 02/2015; 127. DOI:10.1016/j.carpath.2015.02.004 · 1.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Myocardial infarction triggers reparative inflammatory processes programmed to repair damaged tissue. However, often additional injury to the myocardium occurs through the course of this inflammatory process, which ultimately can lead to heart failure. The potential beneficial effects of cell therapy in treating cardiac ischemic disease, the number one cause of death worldwide, are being studied extensively, both in clinical trials using adult stem cells as well as in fundamental research on cardiac stem cells and regenerative biology. This review summarizes the current knowledge on molecular and cellular processes implicated in post-infarction inflammation and discusses the potential beneficial role cell therapy might play in this process. Due to its immunomodulatory properties, the mesenchymal stromal cell is a candidate to reverse the disease progression of the infarcted heart towards heart failure, and therefore is emphasized in this review.
    Cardiovascular Drugs and Therapy 01/2015; DOI:10.1007/s10557-014-6568-z · 2.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The results of stem cell (SC) research in recent years have revealed real possibilities related to their use in the treatment of heart failure. The mobilization of different types of stem and progenitor cells is stimulated by stress factors. The presence of congenital heart defects and corrective surgery is associated with strong stressors that may stimulate the mobilization of SC. This work presents the preliminary results of research on stem cell mobilization of endothelial progenitor cells (EPCs), hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and very small embryonic-like (VSEL) stem cells in children undergoing surgical correction of congenital heart defects. Peripheral blood samples were collected from 21 children. The quality and quantity of stem cells were analyzed by classical and imaging (image stream) flow cytometry, while gene expression was evaluated through quantitative real-time RT-PCR. We determined the expression of genes characteristic of SC. Relevant statistical methods were used to assess the influence that some pathophysiological and demographic factors have on stem cell mobilization. In children with congenital heart defects, the mobilization of different types of SC is observed. The degree of mobilization depends on the pathophysiology of the defect and the patient's age. Strong stress factors related to surgical correction of the defect significantly correlate with the degree of stem cell mobilization.
    Polish journal of cardio-thoracic surgery 12/2013; 4(4):403-409. DOI:10.5114/kitp.2013.39744 · 0.21 Impact Factor

Full-text (2 Sources)

Download
313 Downloads
Available from
May 30, 2014